Figure 1.

A, Screening, randomization, and follow-up through the 12-week treatment period. Six out of the 60 screened individuals were excluded. Three out of 27 participants randomly assigned to placebo did not complete the study. B, Study design and main assessments over the 5 patient visits. FPG, fasting plasma glucose; GA, glycated albumin; H&P, complete history and physical exam; HBA_1c, glycated hemoglobin; HOMA, Homeostatic Model Assessment, HOMA-IR and HOMA-B; IR, insulin resistance; OGTT, oral glucose tolerance test; Rx caps, dispensing of placebo or cinnamon capsules; SF-36, 36-Item Short Form Survey.